Loading...
Loading...
CMMB| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 26.9K |
| Gross Profit | -26.9K |
| Operating Expense | 3,727.4K |
| Operating I/L | -3,754.3K |
| Other Income/Expense | 136.5K |
| Interest Income | 136.5K |
| Pretax | -3,617.8K |
| Income Tax Expense | -0.0K |
| Net Income/Loss | -3,617.8K |
Chemomab Therapeutics Ltd. is a clinical-stage biotech company specializing in the discovery and development of therapeutics for inflammation and fibrosis. Their lead clinical product candidate, CM-101, is a humanized monoclonal antibody designed to target the soluble chemokine CCL24, with applications in treating primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). By developing innovative monoclonal antibody therapies, the company aims to address unmet medical needs in these disease areas, potentially generating revenue through the commercialization of their novel treatments.
